These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34570002)

  • 1. Challenges and Barriers to Adverse Event Reporting in Clinical Trials: A Children's Oncology Group Report.
    Miller TP; Marx MZ; Henchen C; DeGroote NP; Jones S; Weiland J; Fisher B; Esbenshade AJ; Aplenc R; Dvorak CC; Fisher BT
    J Patient Saf; 2022 Apr; 18(3):e672-e679. PubMed ID: 34570002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.
    Miller TP; Fisher BT; Getz KD; Sack L; Razzaghi H; Seif AE; Bagatell R; Adamson PC; Aplenc R
    Pediatr Blood Cancer; 2019 Jul; 66(7):e27747. PubMed ID: 30968531
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eliciting adverse effects data from participants in clinical trials.
    Allen EN; Chandler CI; Mandimika N; Leisegang C; Barnes K
    Cochrane Database Syst Rev; 2018 Jan; 1(1):MR000039. PubMed ID: 29372930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rates of laboratory adverse events by course in paediatric leukaemia ascertained with automated electronic health record extraction: a retrospective cohort study from the Children's Oncology Group.
    Miller TP; Getz KD; Li Y; Demissei BG; Adamson PC; Alonzo TA; Burrows E; Cao L; Castellino SM; Daves MH; Fisher BT; Gerbing R; Grundmeier RW; Krause EM; Lee J; Lupo PJ; Rabin KR; Ramos M; Scheurer ME; Wilkes JJ; Winestone LE; Hawkins DS; Gramatges MM; Aplenc R
    Lancet Haematol; 2022 Sep; 9(9):e678-e688. PubMed ID: 35870472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.
    Reeve BB; Withycombe JS; Baker JN; Hooke MC; Lyons JC; Mowbray C; Wang J; Freyer DR; Joffe S; Sung L; Tomlinson D; Gold SH; Hinds PS
    Pediatr Blood Cancer; 2013 Jul; 60(7):1231-6. PubMed ID: 23335328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using electronic medical record data to report laboratory adverse events.
    Miller TP; Li Y; Getz KD; Dudley J; Burrows E; Pennington J; Ibrahimova A; Fisher BT; Bagatell R; Seif AE; Grundmeier R; Aplenc R
    Br J Haematol; 2017 Apr; 177(2):283-286. PubMed ID: 28146330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting.
    Atkinson TM; Rogak LJ; Heon N; Ryan SJ; Shaw M; Stark LP; Bennett AV; Basch E; Li Y
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):735-743. PubMed ID: 28093637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative.
    Reeve BB; McFatrich M; Pinheiro LC; Weaver MS; Sung L; Withycombe JS; Baker JN; Mack JW; Waldron MK; Gibson D; Tomlinson D; Freyer DR; Mowbray C; Jacobs S; Palma D; Martens CE; Gold SH; Jackson KD; Hinds PS
    Pediatr Blood Cancer; 2017 Mar; 64(3):. PubMed ID: 27650708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials.
    Basch E; Rogak LJ; Dueck AC
    Clin Ther; 2016 Apr; 38(4):821-30. PubMed ID: 27045992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Automated Ascertainment of Typhlitis From the Electronic Health Record.
    Miller TP; Li Y; Masino AJ; Vallee E; Burrows E; Ramos M; Alonzo TA; Gerbing R; Castellino SM; Hawkins DS; Lash TL; Aplenc R; Grundmeier RW
    JCO Clin Cancer Inform; 2022 Sep; 6():e2200081. PubMed ID: 36198128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding current practice, identifying barriers and exploring priorities for adverse event analysis in randomised controlled trials: an online, cross-sectional survey of statisticians from academia and industry.
    Phillips R; Cornelius V
    BMJ Open; 2020 Jun; 10(6):e036875. PubMed ID: 32532777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping child and adolescent self-reported symptom data to clinician-reported adverse event grading to improve pediatric oncology care and research.
    McFatrich M; Brondon J; Lucas NR; Hinds PS; Maurer SH; Mack JW; Freyer DR; Jacobs SS; Baker JN; Mowbray C; Wang M; Castellino SM; Barz Leahy A; Reeve BB
    Cancer; 2020 Jan; 126(1):140-147. PubMed ID: 31553494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes and the evolution of adverse event reporting in oncology.
    Trotti A; Colevas AD; Setser A; Basch E
    J Clin Oncol; 2007 Nov; 25(32):5121-7. PubMed ID: 17991931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in Toxicity Reporting Methods for Early Phase Lung Cancer Treatment Trials at Oncology Conferences.
    Simons EA; Smith DE; Gao D; Camidge DR
    J Thorac Oncol; 2020 Sep; 15(9):1425-1433. PubMed ID: 32353598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium guidance.
    Banerjee AK; Okun S; Edwards IR; Wicks P; Smith MY; Mayall SJ; Flamion B; Cleeland C; Basch E;
    Drug Saf; 2013 Dec; 36(12):1129-49. PubMed ID: 24092596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A systematic review of adverse event reporting in companion animal clinical trials evaluating cancer treatment.
    Giuffrida MA
    J Am Vet Med Assoc; 2016 Nov; 249(9):1079-1087. PubMed ID: 27767430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring adverse social and medical events in public health trials: assessing predictors and interpretation against a proposed model of adverse event reporting.
    Moody G; Addison K; Cannings-John R; Sanders J; Wallace C; Robling M
    Trials; 2019 Dec; 20(1):804. PubMed ID: 31888752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trust but verify: Is there a role for active surveillance in monitoring adverse events in Zimbabwe's large-scale male circumcision program?
    Marongwe P; Gonouya P; Madoda T; Murenje V; Tshimanga M; Balachandra S; Mandisarisa J; Sidile-Chitimbire V; Xaba S; Makunike-Chikwinya B; Holec M; Barnhart S; Feldacker C
    PLoS One; 2019; 14(6):e0218137. PubMed ID: 31181096
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.